The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with ...

The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.

BostonSight’s pilot study, published in Clinical Ophthalmology, explores the use of PROSE scleral lenses as a drug delivery system for cyclosporine 0.05% in treating dry eye disease, showing promising ...

Stuart Therapeutics completed a Phase 3 trial for ST-100, a treatment for dry eye disease, involving a randomized, ...

The trial confirmed linsitinib's favorable safety profile, with no QTc prolongation and manageable adverse events. Late-stage ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical ...

Andrew G. Lee, MD, and Andrew Carey, MD, return for this latest episode of the NeuroOp Guru to discuss whether a dead nerve ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Positive efficacy and safety data were observed at 3 months after a single injection of K8 in this study conducted at the ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...